Significant Weight Loss Observed With CagriSema in REDEFINE 2 …
14 hours ago · The REDEFINE 2 trial (ClinicalTrials.gov Identifier: NCT05394519) evaluated the efficacy and safety of CagriSema in 1206 obese or overweight adults aged 18 years and older with type 2 diabetes. Study participants were randomly assigned to receive subcutaneous CagriSema 2.4mg/2.4mg or placebo once weekly for 68 weeks.
CagriSema Phase 3 Update: Weight Loss of Nearly 16% Seen in REDEFINE 2 …
2 days ago · Novo Nordisk’s investigational combination therapy, CagriSema, achieved significant weight loss in adults with obesity or overweight and type 2 diabetes (T2D), according to results from the phase 3 REDEFINE 2 trial, announced on March 10, 2025. 1 Over the 68-week study period, participants treated with CagriSema experienced an average weight reduction of 15.7%, compared to 3.1% with placebo ...
Novo Nordisk A/S: CagriSema demonstrates superior weight
2 days ago · REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo. The trial included 1,206 randomised people with obesity or overweight and type 2 diabetes and a mean baseline body weight of 102 kg.
Novo Nordisk reports REDEFINE 2 trial of CagriSema achieved …
2 days ago · REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, compared to placebo.
CagriSema Yields Nearly 16% Weight Loss in Phase 3 REDEFINE 2 …
3 days ago · CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss to placebo in adults with obesity or overweight and type 2 diabetes (T2D) in the Phase 3 REDEFINE 2 trial.. As announced by Novo Nordisk on March 10, 2025, these topline results showed the treatment effect of CagriSema led to a weight reduction of nearly –16%, compared with –3% ...
Novo Nordisk A/S: CagriSema demonstrates superior weight
2 days ago · REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo.
Novo Nordisk's CagriSema for Obesity and Type 2 Diabetes …
3 days ago · CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim. A flexible protocol underpinned the REDEFINE 2 trial, enabling patients to adjust their dosage at any time during the study. The maximal dose was used by 61.9% of CagriSema-treated patients after 68 weeks.
Novo Nordisk A/S: CagriSema demonstrates superior weight loss …
2 days ago · REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo. The trial included 1,206 randomised people with obesity or overweight and type 2 diabetes and a mean baseline body weight of 102 kg.
CagriSema Demonstrates Significant Weight Loss at 68 Weeks
1 day ago · “The REDEFINE 2 results confirmed the superior efficacy of CagriSema in people with overweight or obesity and type 2 diabetes”, Martin Holst Lange, executive vice president for development at Novo Nordisk, said in a news release. 1 “We look forward to bringing this second pivotal trial to regulatory authorities with the aim of making this next-generation therapy available to the millions ...
CagriSema Demonstrates Superior Weight Loss in Adults with …
REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo. The trial included 1,206 randomised people with obesity or overweight and type 2 diabetes and a mean baseline body weight of 102 kg.
- Some results have been removed